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Summary
 
We have investigated in vivo roles of CCAAT/enhancer binding protein 
 
g
 
 (C/EBP
 
g
 
) by gene
targeting. C/EBP
 
g
 
-deficient (C/EBP
 
g
 
2
 
/
 
2
 
) mice showed a high mortality rate within 48 h af-
ter birth. To analyze the roles of C/EBP
 
g 
 
in lymphoid lineage cells, bone marrow chimeras
were established. C/EBP
 
g
 
2
 
/
 
2
 
 chimeras showed normal T and B cell development. However,
cytolytic functions of their splenic natural killer (NK) cells after stimulation with cytokines such
as interleukin (IL)-12, IL-18, and IL-2 were significantly reduced as compared with those of
control chimera NK cells. In addition, the ability of C/EBP
 
g
 
2
 
/
 
2
 
 chimera splenocytes to pro-
duce interferon (IFN)-
 
g
 
 in response to IL-12 and/or IL-18 was markedly impaired. NK cells
could be generated in vitro with normal surface marker expression in the presence of IL-15
from C/EBP
 
g
 
2
 
/
 
2
 
 newborn spleen cells. However, they also showed lower cytotoxic activity
and IFN-
 
g
 
 production when stimulated with IL-12 plus IL-18 than control NK cells, as ob-
served in C/EBP
 
g
 
2
 
/
 
2
 
 chimera splenocytes. In conclusion, our study reveals that C/EBP
 
g
 
 is a
critical transcription factor involved in the functional maturation of NK cells.
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T
 
he CCAAT/enhancer binding proteins (C/EBPs)
 
1
 
 be-
long to a family of basic leucine zipper transcription fac-
tors (1, 2). So far six members are isolated and share well
conserved COOH-terminal regions, which contain a basic
region for DNA binding and a leucine zipper motif for
dimerization. Gene targeting revealed that each member
plays a critical role in cellular proliferation and differentiation
in various tissues. For example, nuclear factor (NF)-IL6, also
designated C/EBP
 
b
 
, is essential for macrophage function
(3, 4) and involved in adipocyte differentiation, working
coordinately with C/EBP
 
d
 
 (5). C/EBP
 
a
 
 is essential for
hepatocyte function and adipocyte differentiation (6, 7).
Furthermore, C/EBP
 
e
 
, expressed specifically in myeloid
lineage cells, plays a critical role in granulopoiesis (8).
C/EBP
 
g
 
 is a member of the C/EBP family. C/EBP
 
g
 
can bind to the 
 
m
 
EBP-E binding sites (E sites) in both the
IgH enhancer and the Vh1 promotor and was originally
identified as an Ig enhancer binding protein, Ig/EBP-1 (9,
10). C/EBP
 
g
 
 can also bind to the regulatory elements for
other genes such as G-CSF and IL-4 (11, 12). Although
other members are expressed in a relatively tissue-specific
or inducible manner, expression of C/EBP
 
g
 
 is ubiquitous
and constitutive (9). In addition, C/EBP
 
g
 
 does not contain
transcription activating domains. It can nevertheless inter-
act with other transcription factors through the leucine zip-
per domain and function as a dominant negative form (10).
In some cases, C/EBP
 
g
 
 can augment the DNA binding
ability of other transcription factors (12). Thus, C/EBP
 
g
 
 is
considered to be a regulator for transcription factors with
 
1
 
Abbreviations used in this paper:
 
 AP, activator protein; C/EBPs, CCAAT/
enhancer binding proteins; IRF, IFN regulatory factor; LT, lymphotoxin;
NF, nuclear factor; RAG, recombination activating gene; RT, reverse
transcriptase; STAT, signal transducer and activator of transcription. 
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the leucine zipper domain. However, the biological roles
of C/EBP
 
g 
 
remain unclear.
To clarify in vivo functions of C/EBP
 
g
 
, we have gener-
ated C/EBP
 
g
 
-deficient (C/EBP
 
g
 
2
 
/
 
2
 
)
 
 
 
mice by gene target-
ing. C/EBP
 
g
 
2
 
/
 
2
 
 mice showed a high mortality rate within
48 h after birth, indicating that neonatal survival requires
C/EBP
 
g
 
. By establishing bone marrow chimeras, we found
that C/EBP
 
g
 
 is critical for NK cell functions. NK cells are
large granular lymphocytes derived from the bone marrow
and essential for innate immunity (13, 14). NK cells can me-
diate cytotoxicity against tumor cells and virus-infected cells
and produce immunomodulatory cytokines such as IFN-
 
g
 
.
These activities were impaired in C/EBP
 
g
 
2
 
/
 
2
 
 NK cells,
establishing that C/EBP
 
g
 
 is a novel regulator for func-
tional NK cell maturation.
 
Materials and Methods
 
Generation of C/EBP
 
g
 
2
 
/
 
2
 
 Mice.
 
A BALB/c-derived genomic
fragment including the C/EBP
 
g
 
 gene was provided by Dr. S.
Nagata (Osaka University, Osaka, Japan). As the long arm of the
homology region, an 8.8-kb genomic fragment including the first
exon, the first intron, and part of the second exon was used. The
neomycin resistance gene derived from pMC1Neo-poly(A) (15)
was inserted into the targeting vector to disrupt the basic DNA
binding and leucine zipper regions. A short arm of the homology
region was amplified by PCR. The MC1 herpes simplex virus
thymidine kinase (16) was inserted 5
 
9
 
 upstream of the homolo-
gous region.
E14-1 embryonic stem cells, which were derived from 129/SvJ
(129) mice, were transfected with a linearized targeting vector by
electroporation. Homologous recombinants were identified among
double-resistant clones against G418 and gancyclovir by PCR
and Southern blot analysis. Generation of chimeras and mutant
mice was essentially as described (17).
 
Reverse Transcriptase–PCR for C/EBP
 
g
 
.
 
Splenic B and T cells
were purified from B6 spleen cells using Magnetic Cell Sorter
(MACS
 
®
 
; Miltenyi Biotec) with B220 and CD3 microbeads, re-
spectively. For purification of NK cells, DX5
 
1
 
 cells were first
prepared from B6 spleen cells using MACS
 
®
 
 with biotinylated
DX5 and streptavidin microbeads. Then the cells were stained
with anti-CD3 and anti-DX5. CD3
 
2
 
DX5
 
1
 
 cells were sorted with
EPICS Elite (Coulter Immunology) and used as NK cells for re-
verse transcriptase (RT)-PCR. Total RNAs were extracted from
tissues or cells using Sepazol-RNA I (Nacalai Tesque). Oligo-
dT–primed reverse transcription was performed with Super-
script-RT (GIBCO BRL). Then cDNAs were subjected to PCR
analysis. Primers for C/EBP
 
g
 
 were as follows: sense primer,
5
 
9
 
-GGCCGCTCGGAGTGGAGGCCGTCTGGG-3
 
9
 
; antisense
primer, 5
 
9
 
-ACGTTGTCTGCGAGGCTGTGCGCATGC-3
 
9
 
. The
length of the amplified product was 547 bp. These primers can-
not amplify the genomic DNA because sense and antisense prim-
ers are located in the first and second exons, respectively. Cycling
conditions were 35 cycles of 94
 
8
 
C for 30 s, 65
 
8
 
C for 30 s, and
75
 
8
 
C for 1 min. Primers for 
 
b
 
-actin were as follows: sense primer,
5
 
9
 
-CCCACACTGTGCCCATCTAC-3
 
9
 
; antisense primer,
5
 
9
 
-TACGGATGTCAACGTCACAC-3
 
9
 
. Cycling conditions
were 24 cycles of 94
 
8
 
C for 15 s and 60
 
8
 
C for 30 s.
 
Generation of Radiation Chimeras.
 
The C/EBP
 
g
 
 genotype of
neonates obtained by intercrossing heterozygous mutant mice
was determined by PCR. The splenocytes were taken from the
neonates within 12–18 h after birth and used as sources for he-
matopoietic stem cells. They were injected intravenously into re-
combination activating gene (RAG)2
 
2
 
/
 
2
 
 B6 mice (18) that had
received 12 Gy from an X-ray irradiation system, MBR-1520R
(Hitachi Medical Corp.), before transfer. The recipient mice were
given 1 mg/ml neomycin sulfate and 1,000 U/ml polymixin B in
their drinking water after irradiation and analyzed 6–10 wk after
reconstitution. To evaluate the chimerism in NK cells, we used
surface marker Ly9.1, the allele of which is carried by 129 but not
B6 mice, as used by Ogasawara et al. (19). The genetic back-
ground of the donors in our experiments was a mixture of 129
and B6. Therefore, chimeras, of which the donor was Ly9.1
 
1
 
,
were used for our experiments. In all reconstituted mice used,
 
.
 
99% of CD3
 
2
 
DX5
 
1
 
 cells were positive for Ly9.1 expression
(data not shown).
 
Flow Cytometric Analysis.
 
Single-cell suspensions from thymus,
spleen, or cultured cells were incubated with anti-CD16/32 (Phar-
Mingen) to minimize nonspecific staining. They were then stained
with cocktails of mAbs conjugated to FITC, PE, biotin, or Cy-
Chrome for 20 min at 4
 
8
 
C. The biotinylated Abs were developed
with streptavidin conjugated to PE or Cy-Chrome (PharMingen).
All mAbs, with the exception of PE-labeled anti-IgD (Southern
Biotechnology Associates), were purchased from PharMingen.
Flow cytometric analysis was performed using a FACSCalibur™
with CELLQuest™ software (Becton Dickinson).
 
Proliferation Assay.
 
Fresh splenocytes (10
 
5
 
 cells per well) were
cultured in complete RPMI 1640 (RPMI 1640 medium supple-
mented with 10% FCS, 2-ME, penicillin, and streptomycin) with
10 
 
m
 
g/ml anti-IgM (Zymed Labs.) plus 0.5 
 
m
 
g/ml anti-CD40
(PharMingen), 10 
 
m
 
g/ml LPS (055:B5; Sigma Chemical Co.), 20
ng/ml IL-2 (Genzyme Corp.), 0.1 
 
m
 
g/ml anti-CD3 (PharMin-
gen) plus 0.1 
 
mg/ml anti-CD28 (PharMingen), and 2.5 mg/ml
Con A (Sigma Chemical. Co.) in 96-well plates. 48 h later, they
were pulsed with 0.2 mCi of [3H]thymidine (NEN Research
Products) and cultured for a further 15 h.
Analysis of NK Cell Activity. Splenocytes from bone marrow
chimeras were incubated with 2 ng/ml IL-12, 20 ng/ml IL-18,
and 2 ng/ml IL-12 plus 20 ng/ml IL-18 or 500 U/ml IL-2 for 24 h,
and their cytotoxic activities against YAC-1 cells were measured
as described previously (20, 21). Spontaneous cytotoxic activity
was measured by incubating splenocytes with 51Cr-labeled YAC-1
cells in the absence of cytokines for 4 h.
ELISA and RT-PCR for IFN-g. Splenic cells at 105 cells per
well in 96-well plates were cultured in complete RPMI 1640 in
the presence or absence of 2 ng/ml IL-12 and/or 20 ng/ml IL-18
for 24 h. Amounts of IFN-g in harvested supernatants were mea-
sured by ELISA using Duoset (Genzyme Corp.) according to the
manufacturer’s instructions. The lowest detection limit of ELISA
is 10 pg/ml. Semiquantitative RT-PCR for IFN-g was performed
as described previously (22).
In Vitro Culture of Newborn Spleen Cells. Newborn spleen cells
were cultured in complete RPMI 1640 with 300 ng/ml IL-15
(Genzyme Corp.) at 106 cells per well in 24-well plates. 10 d later,
cells were harvested, washed four times, and used for further
analysis. For cytotoxic activities, harvested cells were incubated
with labeled YAC-1 cells in the absence of cytokines for 4 h. Their
cytotoxic activities against YAC-1 cells were then measured as
described previously (20). For IFN-g measurement, harvested cells
were cultured at 105 cells per well in 96-well plates with 2 ng/ml
IL-12 and 20 ng/ml IL-18 for a further 24 h. Then, amounts of
IFN-g in the culture supernatants were measured with ELISA.
RT-PCR Analysis of Cultured Spleen Cells. Total RNAs were
purified from 10-d–cultured newborn spleen cells with IL-15, re-1575 Kaisho et al.
verse transcribed, and amplified. Primers and amplifying condi-
tions for IL-12Rb1, IL-12Rb2, and IL-18R were described pre-
viously (21).
Western Blot Analysis of Cultured Spleen Cells. Newborn spleen
cells cultured with IL-15 for 10 d were stimulated with 2 ng/ml
IL-12 or 20 ng/ml IL-18 for 20 min and lysed in buffer contain-
ing 20 mM Tris/HCl, pH 8.0, 137 mM NaCl, 5 mM EDTA,
10% glycerol, 1% Triton X-100, 1 mM PMSF, 20 mg/ml aproti-
nin, 20 mg/ml leupeptin, 1 mM Na3VO4, 1 mM EGTA, 10 mM
NaF, 1 mM Na4P2O7, and 10 mM b-glycerophosphate. For sig-
nal transducer and activator of transcription (STAT)4 activation,
the cell lysates were immunoprecipitated with anti-STAT4 Ab
(Santa Cruz Biotechnology) and Protein A–Sepharose (Amer-
sham Pharmacia Biotech). The immunoprecipitates were sepa-
rated on SDS-PAGE, transferred onto a nitrocellulose membrane,
and blotted with antiphosphotyrosine 4G10 (Upstate Biotechnol-
ogy Inc.) or anti-STAT4 Ab. For c-Jun NH2-terminal kinase
(JNK) activation, the cell lysates were separated on SDS-PAGE,
followed by blotting with antiphospho-JNK Ab (Promega Corp.)
or anti-JNK1 Ab (Santa Cruz Biotechnology). Proteins bound to
the Abs were visualized using the enhanced chemiluminescence
system (Dupont).
Results and Discussion
Generation of C/EBPg2/2 Mice. The C/EBPg genomic
locus was disrupted by inserting the neomycin resistance
gene into the second exon (Fig. 1 A). This insertion re-
sulted in disruption of the basic and leucine zipper domains,
which are essential for DNA binding and dimer formation.
Homologous recombinants were obtained through a dou-
ble selection with G418 and gancyclovir. Targeted clones
were injected into B6 blastocysts to generate chimeric
mice, which were bred to achieve germline transmission.
By mating heterozygous mutants, homozygous mutants were
obtained at a frequency of the expected Mendelian ratio
(22.6% of littermates). C/EBPg expression was detected in
wild-type newborn spleens and livers, but not in those of
homozygous mutants as expected (Fig. 1 B). General ap-
pearance at birth was indistinguishable among C/EBPg1/1,
C/EBPg1/2, and C/EBPg2/2 mice. However, only 11% of
homozygous mutants could survive .60 h, although they
were healthy until 12 h after they were born (Table I).
These results indicate that C/EBPg is involved in early
neonatal survival but not embryonic survival. By histologi-
cal examination, C/EBPg2/2 mice at 24 h showed emphy-
sematous changes in their lungs (data not shown). How-
ever, it is not clear at the time of this writing whether the
lung lesions alone can account for the high mortality of ho-
mozygous mutants at the early neonatal stage.
C/EBPg Deficiency Does Not Affect T or B Cell Develop-
ment. C/EBPg is expressed in T and B cells (9). Further-
more, NK cells, which belong to a distinct lymphoid lin-
eage from T and B cells (13, 14), also expressed C/EBPg
mRNA (Fig. 1 C). To investigate in vivo roles of C/EBPg
in these lymphoid lineage cells, we generated bone marrow
chimeric mice by transferring newborn spleen cells into
lethally irradiated, RAG22/2 B6 mice. Thymocytes from
C/EBPg2/2 chimeras showed normal T cell development
(Fig. 2 A). Splenocytes from C/EBPg2/2 chimeras also
showed normal population of CD4182 and CD4281 T
cells (Fig. 2 A). Furthermore, analysis of surface markers
such as B220, IgM, and IgD revealed that B cell maturation
was not disturbed in C/EBPg2/2 chimeras (Fig. 2 A). In
Figure 1. Generation of C/EBPg2/2 mice and expression of C/EBPg mRNA. (A) Schematic representation of the C/EBPg targeting vector, the
C/EBPg genomic locus, and the targeted C/EBPg allele. The targeting vector contains the herpes simplex virus thymidine kinase (HSV-TK) gene 59 up-
stream of the long arm homology region and the neomycin resistance gene (NEO) in the middle of the second exon. (B) RT-PCR analysis of newborn
spleen and liver RNAs from C/EBPg1/1 and C/EBPg2/2 mice. Total RNAs were isolated and analyzed for C/EBPg and b-actin expression by RT-
PCR. M, FX174/HaeIII digest marker. (C) RT-PCR analysis for C/EBPg in lymphoid lineage cells. Total RNAs were isolated from splenic
CD32DX51 (NK), B2201 (B), and CD31 (T) cells and analyzed for C/EBPg and b-actin expression by RT-PCR.
Table I. Postnatal Survival of C/EBPg2/2 Mice
Time Alive (%) No. dead
h
At birth 18 (100) 0
0–12 18 (100) 0
12–24 12 (66.7) 6
24–36 9 (50.0) 3
36–48 3 (16.7) 6
48–60 2 (11.1) 1
.60 2 (11.1) 01576 Impaired Natural Killer Cell Function in C/EBPg-deficient Mice
addition to surface phenotype, proliferative responses to
mitogens or stimulating Abs were not significantly different
between C/EBPg1/1 and C/EBPg2/2 chimeras (Fig. 2 B).
Taken together, these results suggest that C/EBPg is not
essential for functional T and B cell development.
Impaired Splenic NK Cell Activity in C/EBPg2/2 Chimeras.
NK cells can be identified as CD32IL-2Rb1, CD32NK1.11,
or CD32DX51 cells by flow cytometry. However, the
NK1.1 analysis in the chimeras is limited, because only some
mice in a mixed genetic background of 129 and B6 carried
the NK1.1 allele, of which expression is detected on B6 but
not 129 NK cells. Therefore, the NK cell population was an-
alyzed for IL-2Rb and DX5 expression. Splenic CD32IL-
2Rb1 cells in C/EBPg2/2 chimeras were detected at levels
equivalent to those in C/EBPg1/1 chimeras (Fig. 3 A). Fur-
thermore, the frequency of CD32DX51 cells was also com-
parable between C/EBPg1/1 and C/EBPg2/2 chimeras (Fig.
3 A). Percentages of CD32DX51 cells were larger than those
of CD32IL-2Rb1 cells in both control and C/EBPg2/2 chi-
mera splenocytes, as described previously (23).
Next, NK cytotoxicity was measured by YAC-1 cell–
killing activity in the absence or presence of various cyto-
kines (Fig. 3 B). Spontaneous cytotoxicity of C/EBPg2/2
chimera splenocytes (1.0% at 100:1) was impaired as com-
pared with that of control chimera splenocytes (6.4% at 100:1;
Fig. 3 B). IL-12 and/or IL-18 act on NK cells and can en-
hance their cytotoxic activity (21). When stimulated with
these cytokines, C/EBPg2/2 chimera splenocytes also showed
impaired killing activity as compared with control splenocytes
(Fig. 3 B). IL-2 is another stimulatory cytokine for NK cell
activity (24). Decreased killing activity of C/EBPg2/2 chi-
meras was also observed in the presence of IL-2 (Fig. 3 B).
Poly (I:C)-stimulated C/EBPg2/2 chimera splenocytes also
showed lower cytotoxic activity than control splenocytes
(data not shown).
Reduced Ability of C/EBPg2/2 Chimera Splenocytes to Pro-
duce IFN-g in Response to IL-12 and/or IL-18. NK cells con-
stitutively  express both functional IL-12R and IL-18R,
whereas naive T cells do not (21, 25, 26). Therefore,
splenic IFN-g production by stimulation with IL-12 and
IL-18 is dependent on NK but not T cells. To evaluate the
ability of NK cells from chimeric mice to produce IFN-g,
splenocytes were cultured with or without IL-12 and/or
IL-18. 24 h later, cell-free supernatants were harvested and
assayed for IFN-g production with ELISA. Under this
condition, C/EBPg2/2 chimera splenocytes produced much
lower amounts of IFN-g than C/EBPg1/1 chimera sple-
nocytes (Fig. 4 A). IL-12 or IL-18 can induce IFN-g pro-
duction at the transcriptional level in NK cells (27). Consis-
tent with reduced IFN-g production, induction of IFN-g
mRNA was markedly decreased in C/EBPg2/2 chimera
splenocytes (Fig. 4 B). Taken together, these results suggest
Figure 2. Development and function of T and B cells in C/EBPg1/1 and
C/EBPg2/2 chimeras. (A) Flow cytometric analysis of thymi and spleens from
C/EBPg1/1 and C/EBPg2/2 chimeras. Single-cell suspensions from the thymus
and spleen were stained with indicated Abs and analyzed using FACSCali-
bur™ with CELLQuest™ software. The percentages of the quadrants are
shown. (B) C/EBPg1/1 (filled columns) and C/EBPg2/2 (open columns) chi-
mera splenocytes were cultured with indicated mitogens or Abs and analyzed for
their proliferation by measuring [3H]thymidine incorporation. Five independent
experiments were performed with similar results. The data indicate mean 6 SD
of triplicate samples of one representative experiment.1577 Kaisho et al.
that C/EBPg is required for induction of IFN-g by IL-12
and/or IL-18 in NK cells.
IL-15–induced NK Cells from C/EBPg2/2 Newborn Spleens
Showed Impairment of Both Cytotoxic Activity and IFN-g Pro-
duction. NK cell population was analyzed in newborn
splenocytes. Both CD32IL-2Rb1 and CD32DX51 cells
were equivalently detected in C/EBPg1/1 and C/EBPg 2/2
newborn splenocytes (Fig. 5 A). IL-15 can stimulate NK
cell activity and proliferation and is essential for NK cell
development (28, 29). Adult bone marrow cells can gener-
ate NK cells when cultured with IL-15 (28, 30). Wild-type
newborn spleen cells could also give rise to CD32IL-2Rb1
DX51 cells in the presence of IL-15 (Fig. 5 B). In this culture
condition, harvested cell numbers from control (C/EBPg1/1,
n 5 5, and C/EBPg1/2, n 5 3) and C/EBPg2/2 (n 5 7)
mouse spleen cells were 5.7 6 4.1 3 105 and 4.9 6 6.7 3
105 per well, respectively. Surface phenotype of cultured
C/EBPg2/2 cells was identical to that of wild-type cells
(Fig. 5 B). However, NK cells generated from C/EBPg2/2
spleens showed impaired cytotoxic activity against YAC-1
cells as compared with those from C/EBPg1/1 spleens (Fig.
5 C). Furthermore, C/EBPg2/2 NK cells produced lower
amounts of IFN-g in response to IL-12 plus IL-18 than
C/EBPg1/1 and C/EBPg1/2 NK cells (Fig. 5 D). Taken
together, two major NK cell activities, cytotoxic activity
and IFN-g production, were impaired in both C/EBPg2/2
chimera splenocytes and C/EBPg2/2 NK cells generated
in the presence of IL-15 in vitro.
IL-12 and IL-18 Signaling Analysis of C/EBPg1/1 and
C/EBPg2/2 NK Cells. To determine if impaired induction
of IFN-g by IL-12 and IL-18 is caused by decreased expres-
sion of these receptors, we examined their mRNA expres-
sion in C/EBPg1/1 and C/EBPg2/2 NK cells. IL-12Rb1,
IL-12Rb2, and IL-18R expression was equivalent in
C/EBPg1/1 and C/EBPg2/2 NK cells (Fig. 6 A). IL-12 can
Figure 3. NK cell population and
cytolytic activity of C/EBPg1/1
and C/EBPg2/2 chimeras. (A)
Single-cell suspensions from the
chimera splenocytes were stained
with FITC–anti-CD3 and PE–
anti-IL-2Rb Ab (top panels) or
with FITC–anti-CD3 and biotin–
DX5 followed by PE–streptavi-
din (bottom panels). The percent-
ages of NK cell population are
shown. (B) YAC-1 killing analysis
of spleen cells. C/EBPg1/1 ( d)
and 2/2 (s) chimera spleen cells
were incubated without any cy-
tokines for 4 h or with 2 ng/ml
IL-12, 20 ng/ml IL-18, 2 ng/ml
IL-12 plus 20 ng/ml IL-18, or 500
U/ml IL-2 for 24 h, and their cy-
totoxic activities against YAC-1
cells were determined. E/T ratios
are shown on the x-axis. Six
independent experiments were
performed with similar results.
The data indicate mean 6 SD of
triplicate samples of one repre-
sentative experiment.
Figure 4. IFN-g production by chimera splenocytes in response to IL-12
and/or IL-18. (A) Spleen cells from C/EBPg1/1 (filled columns) and
C/EBPg  2/2 (open column) chimera splenocytes were cultured in the
absence (med) or presence of 2 ng/ml IL-12 and/or 20 ng/ml IL-18 for
24 h. Amounts of IFN-g in the culture supernatants were measured by
ELISA. Experiments were independently performed six times with similar
results. The data indicate mean 6 SD of triplicate samples of one rep-
resentative experiment. N.D., not detected. (B) RT-PCR analysis of
C/EBPg1/2 and C/EBPg2/2 chimera splenocytes cultured with 2 ng/ml
IL-12 and 20 ng/ml IL-18 for 24 h. Total RNAs were isolated and ana-
lyzed for IFN-g and b-actin expression by RT-PCR. Experiments were
independently performed three times with similar results.1578 Impaired Natural Killer Cell Function in C/EBPg-deficient Mice
induce tyrosine phosphorylation and activation of STAT4
(31, 32). This pathway was not impaired in C/EBPg2/2 NK
cells (Fig. 6 B). IL-18 can cause phosphorylation and acti-
vation of JNK (33). Equivalent JNK phosphorylation was
observed in C/EBPg1/1 and C/EBPg2/2 NK cells when
stimulated by IL-18 (Fig. 6 C). Taken together, these results
suggest that signaling pathways proximate to these cytokine
receptors are intact in C/EBPg2/2 NK cells.
In this study, we demonstrate that C/EBPg2/2 NK cells
have defects in IFN-g production and cytotoxicity. It has
been shown that several regulatory elements such as the ac-
tivator protein (AP)-1 or NF-kB sites are essential for IFN-g
gene expression by IL-12 and/or IL-18 (34, 35). Although
NF-IL6 is a candidate for heterodimerizing with C/EBPg
(36), it seems unlikely that the heterodimer plays an essen-
tial role. First, no C/EBP sites have been shown to be im-
portant for IFN-g induction. Second, splenic IFN-g pro-
duction in response to IL-12 and/or IL-18 is not impaired
in NF-IL62/2 mice (our unpublished data). It is possible that
C/EBPg plays a critical role in IFN-g gene regulation by
dimerizing with AP-1 components. AP-1 components are
activated by IL-12 or IL-18 and essential for both IL-12–
and IL-18–induced IFN-g promotor activation (34). Fos or
Jun is shown to require C/EBPg in order to efficiently
bind to the regulatory element in the IL-4 promotor (12).
Although further studies are necessary, our results suggest
that C/EBPg regulates IFN-g gene expression. At present,
the possibility that C/EBPg is necessary for expression of
other gene(s) critical for IFN-g gene induction cannot for-
mally be excluded.
IFN-g does not seem to be involved in cytotoxic activ-
ity of NK cells, because NK activity is not remarkably im-
paired in IFN-g2/2 mice (21). Therefore, impaired IFN-g
production cannot account for decreased cytotoxic activity
of C/EBPg2/2 NK cells. Although CD18 is important for
NK cells to recognize target cells (37), surface expression of
CD18 was not decreased in C/EBPg2/2 chimera spleno-
cytes (data not shown). Furthermore, IL-12 and IL-18 could
induce expression of a critical cytolytic mediator, perforin, in
C/EBPg2/2 chimera splenocytes (data not shown). These
results indicate the presence of other target(s) of C/EBPg
that are involved in the cytotoxicity of NK cells.
Figure 5. Characterization of
IL-15–induced NK cells from
newborn spleen cells. (A) Flow
cytometric analysis of newborn
spleen cells. Splenocytes were
taken within 12–18 h after birth
and analyzed for IL-2Rb, DX5,
and CD3 expressions as described
in the legend to Fig. 3 A. The
percentages of NK cell population
are shown. (B) Flow cytometric
analysis of in vitro NK cells. New-
born spleen cells cultured with
IL-15 for 10 d were analyzed us-
ing FACSCalibur™ with CELL-
Quest™ software. (C) YAC-1
killing analysis of in vitro NK cells.
C/EBPg1/1 (d) and C/EBPg2/2
(s) NK cells were analyzed for
their cytotoxic activities. The data
indicate mean 6 SD of triplicate
samples of one representative ex-
periment. (D) IFN-g production
by C/EBPg1/1, C/EBPg1/2, and
C/EBPg2/2 NK cells. IL-15–
induced NK cells were harvested
and cultured at 105 cells/well in
96-well plates for 24 h in the
presence of 2 ng/ml IL-12 and 20
ng/ml IL-18. Amounts of IFN-g
in the culture supernatants were
measured by ELISA. The repre-
sentative data from the same lit-
termates are shown as mean 6
SD of triplicate samples. We an-
alyzed four C/EBPg1/1, eight
C/EBPg1/2, and five C/EBPg2/2
mice for A, five C/EBPg1/1,
three C/EBPg1/2, and seven
C/EBPg2/2 mice for B and D,
and three C/EBPg1/1, one
C/EBPg1/2, and four C/EBPg2/2
mice for C and obtained similar
results.1579 Kaisho et al.
It is noteworthy that in spite of NK cell dysfunction, NK
cell generation is intact in the absence of C/EBPg. This
means that C/EBPg should play critical roles in a late mat-
uration step rather than in an early developmental step. In
contrast, mutant mice established so far manifested impaired
NK cell generation. The IL-15 receptor consists of IL-15Ra,
IL-2Rb, and the common g chain (38–42). Deficiency of
one of these components caused reduction of NK cell num-
bers in vivo and impaired NK cell expansion in vitro (43–45).
Janus kinase (JAK)-3 and STAT5 are essential for IL-15
signaling components. JAK-32/2 or STAT52/2 mice also
showed impairment of NK cell generation (23, 46–49).
Furthermore, IFN regulatory factor (IRF)-1 was found to
be critical for expansion of NK cells (19). This can be ex-
plained by impaired IL-15 production in the bone marrow
microenvironment (19). In these mutants, deficient NK
cell generation is caused by disturbance of IL-15 signaling
or decreased IL-15 production. Membrane lymphotoxin
(LT)a also plays essential roles for NK cell development by
acting independently of IL-15/IRF-1 or upstream of the
IL-15/IRF-1 pathway (50). NK cell generation was se-
verely impaired in LTa2/2 mice. Furthermore, NK cells,
which were generated in vitro with IL-15 from LTa2/2
bone marrow cells, showed intact cytotoxic activity. These
characteristics in LTa2/2 mice are distinct from those in
C/EBPg2/2 mice. In addition, there are two more mutants
with impaired NK cell development, the mechanism of which
is not yet clear. One is deficiency of a winged helix-turn-
helix transcriptional factor, Ets-1 (51). The other is defi-
ciency of Id2, an inhibitor for transcription factors with
helix-loop-helix domains (52).
At present, little is known about the molecular mecha-
nisms that regulate NK cell functions or development. Our
study clearly reveals that C/EBPg is critically involved in
functional NK cell maturation. Identification of the target
genes regulated by C/EBPg will clarify the molecular
mechanism of NK cell functions.
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